Correlation of ACE2 with RAS components after Losartan treatment in light of COVID-19

Figures

• 

  Figure 1. Response of ACE2 to LOS differed among patients. (A) Schematic diagram illustrates the upregulation of ACE2 after LOS treatment. (B) ACE2 log2 fold change expression levels of individual patient at baseline and 6 weeks after LOS treatment.

• 

  Figure 2. Response of RAS components to LOS among patients. (A) Increase and decrease response of AT1R of individual patients at baseline and at 6 weeks of LOS treatment. (B) Increase and decrease response of AGT of individual patients at baseline and at 6 weeks of LOS treatment. (C) Increase and decrease response of AT2R of individual patients at baseline and at 6 weeks of LOS treatment. (D) Increase and decrease response of MAS1 of individual patients at baseline and at 6 weeks of LOS treatment.

• 

  Figure 3. Negative Pearson correlation of RAS component to LOS treatment. (A) Negative correlation of AT1R with ACE2 (r = − 0.41). (B) Negative correlation of AT1R with AGT (r = − 0.37). (C) Negative correlation of AT1R with AT2R (r = − 0.36). (D) Negative correlation of AT1R with MAS1 (r = − 0.53). Calculation of correlation coefficient and testing the significance of the correlation coefficient were performed using R (* denotes P < 0.005).

• 

  Figure 4. Positive Pearson correlation of RAS component to LOS treatment. (A) Positive correlation of AGT with AT2R (r = 0.58). (B) Positive correlation of ACE2 with AT2R (r = 0.46). (C) Positive correlation of AGT with MAS1 (r = 0.82, ***P < 0.001). (D) Positive correlation of ACE2 with MAS1 (r = 0.92, ***P < 0.001). Calculation of correlation coefficient and testing the significance of the correlation coefficient were performed using R (* denotes P < 0.005).

• 

  Figure 5. Schematic diagram shows controversy of losartan treatment for Covid-19. Determining the MAS1 expression could predict the response to SARS-CoV-2 viral load for patients who are already on LOS medication for pre-existing condition.